As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
6 Analysts have issued a Coeptis Therapeutics forecast:
6 Analysts have issued a Coeptis Therapeutics forecast:
| Dec '23 | 
    +/-
   
    %
   | ||
| Revenue | - - | 
    -
 | |
| Gross Profit | - - | 
    -
 | |
| EBITDA | -20 -20 | 
    -
 | |
| EBIT (Operating Income) EBIT | -21 -21 | 
      
        
        67%
      
      
        
        67%
      
 | |
| Net Profit | -21 -21 | 
      
        
        69%
      
      
        
        69%
      
 | |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company. It develops innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.
| Head office | United States | 
| CEO | David Mehalick | 
| Employees | 6 | 
| Founded | 2017 | 
| Website | coeptistx.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


